# Sackler Family A two-branch American pharmaceutical dynasty that, over roughly forty years between OxyContin's 1996 launch and the 2024 Supreme Court ruling in [[Harrington v. Purdue Pharma]], became the wealthiest family of the American opioid epidemic — and then became the public face of the dynasty whose reputation collapsed most completely under the weight of its own product. The Sacklers are the test case for **dynasty as criminal liability laundered through philanthropy**: a single family that built a fortune of roughly $14 billion (Forbes 2016 peak), spread its name across the museum and medical-school architecture of three continents, and was systematically de-named by those same institutions in the space of four years (2018–2022) once the public death-count math became inescapable. The dynasty's relationship to the rest of this knowledge base is unusual. Most of the families in the Dynasties folder are *politically* active in a partisan sense — donors, officeholders, ideological movement-builders. The Sacklers are not. Their political relevance is structural: they are the canonical case of (a) how dynastic wealth captures regulatory institutions, (b) how the bankruptcy code can be used as a wealth-preservation tool against mass-tort liability, and (c) how the class asymmetry between corporate drug crime and individual drug crime works in practice (see [[War on Drugs Timeline]] for the parallel carceral track). The opioid crisis is the largest pharmaceutical-driven mass-casualty event in American history, and the Sackler family is the load-bearing actor. → For the chronological story, see **[[Opioid Crisis Timeline]]**. For the corporate vehicle, see **[[Purdue Pharma]]**. This file is the **entity** — who they are, how the branches divide, and where the dynasty sits now. --- ## The Family Tree ``` ┌──────────────────────────────────────────────┐ │ FOUNDING GENERATION (Brooklyn, 1910s–1940s) │ │ │ │ Isaac & Sophie (née Greenberg) Sackler │ │ Galician/Polish-Jewish immigrants │ │ Brooklyn grocers │ │ ↓ │ │ Three sons, all NYU/Glasgow-trained MDs: │ └──────────────────────────────────────────────┘ │ ┌─────────────────┼─────────────────┐ ▼ ▼ ▼ ARTHUR M. MORTIMER D. RAYMOND R. SACKLER SACKLER SACKLER (1913–1987) (1916–2010) (1920–2017) eldest; middle; youngest; marketing/ Purdue Purdue publishing/ co-president co-president art-collecting (UK base, (US base, empire hon. KBE 1995) Purdue Pharma) │ │ │ │ │ │ ARTHUR'S BRANCH SIDE A SIDE B (estate sold (Mortimer's (Raymond's his third to heirs) heirs) the brothers, └──── together, the "Purdue Sacklers": 1987; not a owned Purdue through the OxyContin Purdue party) era; named in the 2025 settlement ``` ``` SIDE A + SIDE B: the "Purdue Sacklers" (bankruptcy-court usage: Side A = Mortimer's family, Side B = Raymond's family; Arthur's branch is neither) SIDE A MORTIMER D. SACKLER ─── three marriages, seven children: (1916–2010) m.1 Muriel Lazarus ──────── • Ilene Sackler Lefcourt (b. 1946 or 1948; sources differ) • Kathe Sackler (b. 1948) • Robert Mortimer Sackler (predeceased his father) m.2 Gertraud "Geri" Wimmer ─ • Samantha Sophia Sackler Hunt • Mortimer D.A. Sackler (b. 1971 or 1972) [also: Mortimer Jr.] m.3 Theresa Rowling ─────── • Marissa Sackler (b. 1949; m. 1980; • Sophia Sackler widow; UK-based; • Michael Sackler Purdue board to 2018) SIDE B RAYMOND R. SACKLER ─── m. Beverly Sackler (1924–2019); two sons: (1920–2017) • RICHARD SACKLER (b. 1945) • JONATHAN SACKLER (1955–2020) │ └── David Sackler (b. 1979/80) Richard's son / Jonathan's nephew (board member 2012–2018) ``` ``` ARTHUR'S BRANCH (neither Side A nor Side B) (the "Met Wing Sacklers") ARTHUR M. SACKLER ─── three marriages: (1913–1987) m.1 Else Jorgensen → Carol, Elizabeth m.2 Marietta Lutze → Arthur F., Denise m.3 Jillian Lesley Tully Sackler (d. June 2025, aged 84; long-time head of the Dame Jillian and Dr. Arthur M. Sackler Foundation for the Arts) Position: Arthur's branch was bought out for ~$22.4M in 1987 (after Arthur's death) ($22.35M per ProPublica) by Mortimer + Raymond, BEFORE OxyContin was developed (1995–96). Arthur's heirs maintain they have no OxyContin liability. ProPublica reporting suggests indirect benefit via retained interests in Mundipharma international affiliates. Arthur's branch and the Purdue Sacklers are estranged. ``` --- ## Founding Generation: The Three Brothers (1913–1952) **Arthur M. Sackler** (1913–1987), **Mortimer D. Sackler** (1916–2010), and **Raymond R. Sackler** (1920–2017) were the three sons of Isaac and Sophie Sackler, Galician/Polish-Jewish immigrants who ran a Brooklyn grocery business. All three brothers earned medical degrees — Arthur at NYU, Mortimer and Raymond at the University of Glasgow (after US medical-school antisemitism blocked them) and then NYU. The family identity of *physician-businessmen* was set in the first generation: they were not pharma executives who happened to have medical credentials, they were doctors who built a pharma business as an extension of medical practice. In 1952, the three brothers pooled their savings — Arthur supplied the bulk of the capital from his medical-advertising income — and bought the **Purdue Frederick Company**, a small generic-drug manufacturer in lower Manhattan, for **$50,000**. Purdue Frederick was best known for laxatives (Senokot), Betadine antiseptic, and earwax remover. It was a sleepy business. The brothers ran it for thirty years as a respectable mid-tier pharma company. The transformative drug would not come until [[OxyContin]] in 1996 — by which time only Mortimer and Raymond, and their adult children, controlled it. **Arthur Sackler** is the most consequential figure of the founding generation, even though he died before [[OxyContin]] existed. His career was in pharmaceutical advertising and medical publishing, not pharma operations. At the William Douglas McAdams advertising agency (which Arthur eventually owned), he invented or popularized: full-page color drug ads in medical journals (most notably *The Journal of the American Medical Association*); direct-to-physician sales-rep "detailing"; sponsored continuing-medical-education programs; the use of paid physician opinion-leaders; and the publication of "scientific" supplements bankrolled by drug companies. The Medical Advertising Hall of Fame credited him with shaping "pharmaceutical promotion as we know it today." His 1960 launch of the *Medical Tribune* — a weekly newspaper that eventually reached 600,000 physicians — institutionalized the blurring of editorial and promotional content in medical media. The Valium campaign (1963 onward) made Arthur extraordinarily wealthy. He took commission on Roche's Valium (diazepam) sales, and Valium became the most-prescribed drug in America from 1968 to 1982 and the first pharmaceutical to top $100 million in annual sales. The benzodiazepine dependency epidemic that emerged in the 1960s–70s was, Patrick Radden Keefe argues in *Empire of Pain*, a small-scale rehearsal for the opioid epidemic: a Sackler-marketed drug promoted as safer than predecessors, prescribed at massive scale, and producing widespread iatrogenic dependence. The Sackler heirs dispute the parallel. **Mortimer and Raymond** were the operational pharma brothers. Mortimer eventually relocated to Europe and oversaw the development of the international Sackler pharma footprint (the Mundipharma group of affiliated companies, structured to keep cross-border operations privately held by family trusts and out of US disclosure). Raymond ran the US operation. Both married into wealth and society, and both leveraged the Purdue fortune into extensive philanthropy in medical research, education, and the arts — building the institutional reputational armor the family would later see stripped away. **Mortimer was made an honorary Knight Commander of the Order of the British Empire (KBE) in 1995** (one source: Wikipedia). As an honorary award it did not carry the title "Sir." It recognized his charitable contributions, primarily to UK museums and medical schools. The honour has not been formally rescinded. --- ## The Schism: Arthur's Branch vs. the Purdue Sacklers (1987) > [!note] Naming (corrected 2026-10-06) > In the Purdue bankruptcy, **Side A is Mortimer's family and Side B is Raymond's** (Judge McMahon, S.D.N.Y., Dec 16 2021; Debtwire). Arthur's branch is neither; it sold out in 1987. This page earlier used "A-side" for Arthur's branch and "B-side" for both Purdue families, which was wrong. The most consequential intra-family event happened in 1987, when Arthur Sackler died at age 73. Under the terms of an existing buy-sell arrangement, Mortimer and Raymond purchased Arthur's one-third stake in the family enterprise for approximately **$22.4 million**. Arthur's widow Jillian and his children from earlier marriages thus formally exited the Purdue ownership structure — eight years before [[OxyContin]]'s 1996 launch. This produced two diverging family branches: - **Arthur's branch** — Arthur's descendants and his widow Jillian (who died in June 2025). They own and run the Dame Jillian and Dr. Arthur M. Sackler Foundation for the Arts, Sciences, and Humanities. They have spent the OxyContin era arguing, loudly and continuously, that Arthur was bought out before OxyContin existed and bears no responsibility for the opioid crisis. Their argument is technically true at the corporate-ownership level. *ProPublica* reporting in 2019 surfaced documents suggesting Arthur's heirs may have retained interests in Sackler international affiliates that benefited from OxyContin sales abroad, but Arthur's heirs dispute this. They have been publicly hostile to the Purdue Sacklers throughout the crisis. - **Side A (Mortimer's family) and Side B (Raymond's family)** — together the "Purdue Sacklers." These are the eight heirs named in the 2025 settlement: Richard, Kathe, Mortimer D.A. (Mortimer Jr.), Ilene, David, Theresa, and (deceased but represented by their estates) Beverly and Jonathan. They owned and controlled [[Purdue Pharma]] through the OxyContin era; they sat on the Purdue board through the 2007 plea and the 2010 reformulation and the 2019 bankruptcy. They are the Sacklers in the **$7.4 billion** settlement. The two branches do not speak. Jillian Sackler has given multiple interviews demanding that the media stop saying "the Sacklers" caused the opioid crisis, and instead say "the Mortimer and Raymond Sacklers." The media has not, on the whole, complied. --- ## Second Generation: The Operational Sacklers The second generation of Sides A and B — the people who actually ran Purdue Pharma during the OxyContin era — are these: - **[[Richard Sackler]]** (b. 1945) — Raymond's son. Yale Medical School (MD, no clinical practice). Joined Purdue in 1971 and rose through the company; **President of Purdue Pharma 1999–2003**; co-chair of the board afterward. The most-cited Sackler in the internal documents released during the bankruptcy and state-AG investigations. Author of the 1996 launch-celebration email ("We have to hammer on abusers...") and the 2008 strategic email pushing higher doses ("We have run out of patients to put on opioids; future growth requires increasing dosage in existing patients"). The face of Purdue-Sackler accountability — and, in public reporting, the most ideologically committed of the second generation to the OxyContin push. - **[[Jonathan Sackler]]** (1955–2020) — Raymond's other son. Also on the Purdue board. Predeceased the major settlements; estate is part of the 2025 deal. Politically, his most-public profile in his lifetime was as a school-reform donor — funding a network of charter-school and education-reform organizations. - **[[Kathe Sackler]]** (b. 1948) — Mortimer's daughter. Medical doctor by training. Purdue board member through the OxyContin era. Per the Massachusetts and New York complaints, worked with Purdue staff in 2014 on "Project Tango," a plan to expand Purdue's commercial reach into the addiction-treatment market — a remarkable concept (the company that profited from the addiction now profiting from the treatment) that the company did not execute publicly. - **[[Mortimer D.A. Sackler]]** (b. 1971 or 1972) — Mortimer's son by his second wife, Gertraud Wimmer (also called Mortimer Jr.). Purdue board member. Among the named defendants in the most-aggressive state-AG cases (Massachusetts, New York). - **[[Theresa Sackler]]** (b. 1949) — Mortimer's third wife (married 1980) and widow; stepmother to his older children; UK-based. Purdue board member. Chair of the Sackler Trust UK (which announced in 2019 that it would stop new donations to UK arts institutions). Among the named defendants. - **[[Ilene Sackler Lefcourt]]** (b. 1946 or 1948; sources differ) — Mortimer's daughter by his first wife, Muriel Lazarus. Purdue board member. - **[[Beverly Sackler]]** (1924–2019) — Raymond's wife. Long-time board member. Deceased; estate part of the settlement. **Third generation operational involvement:** - **[[David Sackler]]** (b. 1979/80) — Richard's son, Jonathan's nephew. Purdue board member 2012–2018. The third-generation Sackler with the most direct OxyContin-era operational footprint. After leaving the board, attempted (unsuccessfully) to reposition the family publicly via interviews acknowledging "regret" without acknowledging legal culpability. The remaining second- and third-generation Sacklers — there are many — were not on the Purdue board and are not named in the settlement. The named-defendant list is the *board-member* list, which is the legal exposure list. --- ## The Business Empire (overview — see [[Purdue Pharma]] for operational detail) The Sackler commercial structure runs on three concentric rings: 1. **[[Purdue Pharma]]** — The US operating company. Owner of [[OxyContin]] and the historic profit center. Reorganized through bankruptcy as a public-benefit company (Knoa Pharma); the plan was confirmed in November 2025 and took effect May 1, 2026. 2. **[[Mundipharma]]** — The international network of affiliated pharma companies operating in Europe, Asia, Latin America, the Middle East, and Africa. Structured to keep international Sackler pharma operations privately held by family trusts, often through Bermuda / Jersey / Mondaine vehicles. Mundipharma has been independently marketing OxyContin and other opioids in jurisdictions with weaker pharmacovigilance, raising concerns of a coming international opioid wave. The Sackler family retains Mundipharma in the bankruptcy framework. 3. **[[Rhodes Pharmaceuticals]]** — A US generic-pharma subsidiary set up by Purdue in 2007 (immediately after the federal guilty plea), in part to produce generic oxycodone and other opioids. Functioned as a second commercial arm for the same family during the post-plea period. The family transferred at least **$11 billion** out of Purdue Pharma to family-controlled trusts and offshore vehicles between approximately 2008 and 2019 — the period bracketed by the 2007 plea and the 2019 bankruptcy filing. These transfers are documented in audited financials; they are not concealment in a criminal sense. They were timed, however, to remove assets from Purdue's reach before the wave of state-AG litigation could compel them into a bankruptcy estate. --- ## The Philanthropic Empire (and Its Collapse) The Sackler reputation-laundering machinery was the most elaborate of any American pharmaceutical dynasty. Three institutional categories: 1. **Major art museums**: The Metropolitan Museum of Art (Sackler Wing of Egyptian Antiquities, including the Temple of Dendur, opened 1978); the Guggenheim (Sackler Center for Arts Education); the [[Smithsonian Institution]] (Arthur M. Sackler Gallery, opened 1987); the Louvre (Sackler Wing, opened 1997); Tate Modern; the Victoria & Albert; the Royal Academy; the Serpentine Galleries (Sackler Serpentine). 2. **Medical schools and universities**: Harvard (Arthur M. Sackler Museum and Sackler Building at Harvard Medical School); NYU (Sackler Institute); Tufts (Sackler Center for Medical Education and the Sackler School of Graduate Biomedical Sciences); Yale (Sackler Institute for Biological Studies); Columbia; Oxford; the Sackler Faculty of Medicine at Tel Aviv University; the King's College London Sackler Institute. 3. **Direct biomedical-research foundation grants**, particularly through the Raymond and Beverly Sackler Foundation, the Mortimer D. Sackler Foundation, and (separately) the Dame Jillian and Dr. Arthur M. Sackler Foundation for the Arts. Total philanthropic giving (estimated): over **$1 billion** across the family's history. Between roughly 2018 and 2022 — driven by the Nan Goldin / P.A.I.N. protest movement and the *Empire of Pain* reporting cycle — most of these institutions either declined further Sackler donations, removed the Sackler name from existing galleries, or both. The dominoes (selected): - 2019-03 — Sackler Trust UK suspends donations. - 2019-03 — Tate galleries decline further Sackler money. - 2019-07 — The Louvre removes the Sackler name from its Oriental Antiquities wing. - 2021-12 — The Metropolitan Museum removes the Sackler name from seven gallery spaces, including the Temple of Dendur. - 2022 — Harvard committee recommends Sackler de-naming; final report 2024. - 2024-08 — Harvard formally removes Sackler name from the Arthur M. Sackler Museum and the Sackler Building at the Medical School. The collapse of the reputation-laundering apparatus was, in the narrow art-history sense, a vindication of the protest movement. In the larger sense, the de-naming does not return the money: the buildings remain, the institutions retain the buildings, and the Sacklers retain the wealth. The reputation is the only asset that has been clawed back. **Arthur's branch** (Jillian Sackler, until her death in 2025, and Arthur's heirs) has been particularly vocal in objecting to de-namings of institutions endowed primarily by Arthur — arguing that Arthur predates OxyContin and that his philanthropy is being conflated with the Purdue Sacklers' culpability. Many de-namings have proceeded over their objection. --- ## Power Arc: Where the Dynasty Sits Now The dynasty is in the **declining / contested** phase. As of May 2026: - The 2025 settlement is finalized: Sacklers will pay **$6.5B over 15 years**; Purdue Pharma pays $900M; total **$7.4B**. - The family's release protects them only from claimants who opted into the settlement; opt-outs can still sue individual family members (post-*Harrington* structure). - **Zero family members face criminal charges** for OxyContin marketing. The 2007 plea was at the corporate level; the 2020 plea was at the corporate level; the family itself has never been charged. - Family aggregate wealth (post-settlement, projected after payment schedule completes) is estimated at **~$11 billion** — barely reduced relative to pre-bankruptcy levels, because the $11B in pre-bankruptcy transfers generated investment returns that approximately match the settlement payment stream. - The Sackler name has been removed from most major US and UK arts and academic institutions. - [[Mundipharma]] continues to operate internationally. - Political activity: the Sacklers are **not** significant political donors at the federal level, despite their wealth. The family's political profile remains low-key by major-donor standards. The exception is Jonathan Sackler (deceased 2020), who funded charter-school and education-reform organizations during his lifetime. The family does not have a "Sackler political program" in the sense that, say, [[the Kochs]] or Mercers do. The dynasty's **succession question** is essentially closed. Purdue Pharma ceased operating as such on May 1, 2026, when the plan took effect and its business passed to Knoa Pharma, a public-benefit company. [[Mundipharma]] continues but is not a growth story. The third-generation Sacklers (including David) appear, from public reporting, to be pivoting toward private investment and philanthropic-board positions rather than continuing in pharma operations. The Sackler dynasty as a *commercial entity* is winding down; the Sackler dynasty as a *wealth-holding extended family* will persist indefinitely. The dynasty's principal post-2025 challenge is the long tail of individual civil suits — *Harrington v. Purdue Pharma* opened the door, and the settlement permits opt-out plaintiffs to continue. Several thousand individual plaintiffs and a number of states have signaled they will not foreclose pursuing individual family members further. As of 2026, the legal long-tail is unresolved. --- ## Internal Dissent and External Critics Unlike the [[Trump Family]] (with [[Mary L. Trump]]) or the Murdoch dynasty (with [[James Murdoch]]), the Sacklers have no prominent *family* dissenter. The closest analog is the split between Arthur's branch and the Purdue Sacklers, which is not so much dissent as repudiation — Arthur's branch arguing it bears no responsibility for what Mortimer's and Raymond's branches did. External critics include: - **Nan Goldin** — photographer and OxyContin survivor; founder of Prescription Addiction Intervention Now (P.A.I.N.); the central figure in the museum-de-naming campaign; subject of Laura Poitras's 2022 documentary *All the Beauty and the Bloodshed*. - **Patrick Radden Keefe** — *New Yorker* reporter; author of *Empire of Pain* (2021), the standard work on the dynasty. - **Barry Meier** — former *NYT* reporter; author of *Pain Killer* (2003 / updated 2018), the first major journalistic accounting of OxyContin's launch. - **Beth Macy** — author of *Dopesick* (2018), focused on the Appalachian epicenter of the crisis. - **The state attorneys general** — particularly [[Letitia James]] (NY), [[Maura Healey]] (MA, later MA governor), and the Connecticut and Massachusetts AGs whose civil cases produced the most damaging document releases. --- ## Cross-References - **The chronological story:** [[Opioid Crisis Timeline]] - **The corporate entity:** [[Purdue Pharma]] - **The drug itself:** [[OxyContin]] - **The Supreme Court ruling:** [[Harrington v. Purdue Pharma]] - **The parallel carceral track:** [[War on Drugs Timeline]] - **The historical philanthropy-as-laundering archetype:** [[Andrew Mellon]] - **The state AG who recovered $1.5B:** [[Letitia James]] ## Open stubs to build - [[Mundipharma]] — international affiliate group; potentially the next OxyContin-style wave abroad - [[Rhodes Pharmaceuticals]] — Purdue's generic-opioid spinoff - [[Empire of Pain]] — Patrick Radden Keefe's 2021 book, the standard reference - [[Dopesick]] — Beth Macy's 2018 book on the Appalachian epicenter - [[Pseudoaddiction]] — the term that powered the dose-escalation playbook - Individual second-gen profiles beyond stubs (Richard, David, Kathe in particular merit fuller treatment) - Nan Goldin person file — the artist-activist behind the de-naming campaign - Russell Portenoy person file — the pain-management physician central to the 1990s opioid-prescribing pivot